Details for Patent: 11,110,087

Which drugs does patent 11,110,087 protect, and when does it expire?

Patent 11,110,087 protects VENCLEXTA and is included in one NDA.

This patent has twenty-two patent family members in ten countries.

Summary for Patent: 11,110,087

Title:	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Abstract:	The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Inventor(s):	Sampath; Deepak (South San Francisco, CA), Klein; Christian (Iffeldorf, DE), Fairbrother; Wayne John (South San Francisco, CA), Enschede; Sari L. Heitner (River Forest, IL), Humerickhouse; Rod A. (Highland Park, IL), Roberts; Andrew W. (Melbourne, AU), Seymour; John F. (Melbourne, AU)
Assignee:	GENENTECH, INC. (South San Francisco, CA) HOFFMANN-LA ROCHE INC. (Little Falls, NJ) ABBVIE INC. (North Chicago, IL)
Application Number:	17/187,468
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,110,087
Patent Claim Types: see list of patent claims	Use;

United States Patent 11,110,087: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 11,110,087, titled "COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR," is a significant patent in the field of cancer treatment. This patent, granted on September 7, 2021, involves a combination therapy that combines a type II anti-CD20 antibody with a selective BCL-2 inhibitor. Here, we delve into the scope, claims, and the broader patent landscape surrounding this invention.

Inventors and Assignees

The patent was invented by a team of researchers including Deepak Sampath, Christian Klein, Wayne Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, and John F. Seymour. The assignees of the patent are Genentech, Inc., Hoffmann-La Roche Inc., and AbbVie Inc.[4].

Scope of the Patent

The patent focuses on a combination therapy for the treatment of cancer, particularly cancers that express CD20, such as certain types of lymphoma. The therapy involves the use of a type II anti-CD20 antibody, exemplified by the GA101 antibody, in combination with a selective BCL-2 inhibitor. This combination is designed to enhance the efficacy of cancer treatment by targeting multiple pathways involved in cancer cell survival and proliferation[4].

Claims of the Patent

The patent includes 29 claims that define the scope of the invention. These claims cover various aspects of the combination therapy, including:

• The composition of the type II anti-CD20 antibody and the selective BCL-2 inhibitor.
• Methods of administering the combination therapy.
• Specific dosages and treatment regimens.
• The use of the combination therapy for treating CD20-expressing cancers.

The claims are structured to ensure broad protection for the inventors while also providing clarity on what constitutes the invention[4].

Patent Claims Analysis

The claims in this patent are carefully crafted to balance breadth and specificity. Here are some key points:

• Independent Claim Length and Count: Research suggests that narrower claims, as measured by independent claim length and count, are associated with a higher probability of grant and a shorter examination process. The claims in this patent are detailed but not overly broad, which likely contributed to its successful grant[3].
• Claim Construction: The claims are constructed to cover the essential elements of the combination therapy, ensuring that any similar therapies would infringe on these claims. This is crucial for maintaining the patent's validity and enforceability[4].

Patent Landscape

Related Patents and Prior Art

The patent cites several prior art documents, including U.S. patents and international publications. These references indicate that the inventors were aware of existing treatments and technologies in the field and have built upon them to create a novel combination therapy. For example, references to earlier work by Bruncko et al. and Elmore et al. highlight the evolutionary nature of this research[4].

Competing Therapies

The patent landscape in cancer treatment is highly competitive, with numerous patents covering various therapeutic approaches. The combination of a type II anti-CD20 antibody with a selective BCL-2 inhibitor represents a unique strategy that differentiates it from other treatments. This differentiation is crucial for securing market share and protecting the invention from infringement[4].

Regulatory Environment

The regulatory environment for biologic drugs, including those covered by this patent, is stringent. The FDA and other regulatory bodies require rigorous testing and clinical trials to ensure safety and efficacy. The patent's claims must align with these regulatory requirements, which can impact the scope and enforcement of the patent[5].

Litigation and Enforcement

Patents in the biotechnology and pharmaceutical sectors are often subject to litigation. The recent trends in patent litigation, such as the use of the "compelling merits" standard by the PTAB, highlight the complexities involved in defending and enforcing patents. The owners of this patent must be prepared to defend their invention against potential challenges and ensure that any litigation aligns with the evolving standards and practices in patent law[1].

Expiry and Biosimilars

The patent's term is subject to the standard 20-year period from the filing date, adjusted for any delays during the examination process. As the patent approaches its expiry, the landscape for biosimilars will become relevant. Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. The expiry of this patent will open the door for biosimilar manufacturers to enter the market, potentially changing the competitive dynamics[5].

Clinical Significance

The combination therapy described in this patent has significant clinical implications. By targeting both CD20 and BCL-2 pathways, it offers a potentially more effective treatment for patients with CD20-expressing cancers. Clinical trials and real-world data will be crucial in establishing the efficacy and safety of this therapy, which could lead to its widespread adoption and impact on patient outcomes[4].

Economic Impact

The economic impact of this patent is substantial. The development and commercialization of this combination therapy involve significant investment. The patent protection ensures that the inventors and assignees can recoup their investment through exclusive rights to the market. This exclusivity can also influence pricing and access to the therapy, which are critical considerations in the healthcare sector[4].

Key Takeaways

• Combination Therapy: The patent covers a novel combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor.
• Scope and Claims: The claims are detailed and specific, ensuring broad protection while maintaining clarity.
• Patent Landscape: The patent is part of a competitive landscape in cancer treatment, with ongoing litigation and regulatory challenges.
• Clinical and Economic Impact: The therapy has significant clinical and economic implications, including potential for improved patient outcomes and market exclusivity.

FAQs

What is the main focus of United States Patent 11,110,087?

The main focus of this patent is a combination therapy for cancer treatment, specifically using a type II anti-CD20 antibody and a selective BCL-2 inhibitor.

Who are the inventors and assignees of this patent?

The inventors include Deepak Sampath, Christian Klein, and others, while the assignees are Genentech, Inc., Hoffmann-La Roche Inc., and AbbVie Inc.

How many claims are included in this patent?

The patent includes 29 claims that define the scope of the invention.

What is the significance of the combination therapy described in this patent?

The combination therapy targets multiple pathways involved in cancer cell survival and proliferation, potentially offering a more effective treatment for CD20-expressing cancers.

When is the patent expected to expire?

The patent's term is subject to the standard 20-year period from the filing date, adjusted for any delays during the examination process. As of the current date, the exact expiry date would be around 2041, considering the filing date of February 26, 2021.

Cited Sources

1. Patent Filings Roundup: Light Week in District Court Buoyed by IV ... - IP Watchdog
2. Pharmaceutical drugs covered by patent 11,110,087. Claims ... - Drug Patent Watch
3. Patent Claims and Patent Scope - SSRN
4. United States Patent - googleapis.com - US Patent 11,110,087 B2
5. When do biologic drug patents expire and when will biosimilars ... - Drug Patent Watch

Drugs Protected by US Patent 11,110,087

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No						TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No						TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes						TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE

International Family Members for US Patent 11,110,087

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2884307
China	104768581
China	111437386
China	111481552
European Patent Office	2892557
European Patent Office	3919079
Hong Kong	1212240